1 / 23

Expectations for Facilities & cGMPs

Expectations for Facilities & cGMPs. Biological Response Modifiers Advisory Committee Meeting October 9, 2003 Nicholas Obiri, Ph.D. CBER. Scope. Regulatory Authority Facility Design Principles Environmental and Process Control Aseptic Processing. Regulatory Authority.

lynette
Télécharger la présentation

Expectations for Facilities & cGMPs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Expectations for Facilities & cGMPs Biological Response Modifiers Advisory Committee Meeting October 9, 2003 Nicholas Obiri, Ph.D. CBER

  2. Scope • Regulatory Authority • Facility Design Principles • Environmental and Process Control • Aseptic Processing

  3. Regulatory Authority • Public Health Service Act Section 351 • Authority for licensing biological products when certain conditions are met

  4. Regulatory Authority contd. • Title 21 CFR Section 601.2(d) • Approval of an application shall constitute a determination that the establishment(s) and product meet applicable requirements to ensure the continued safety, purity and potency of such products. • The requirements include the applicable regulations (21 CFR 210-211; 600s; 800s).

  5. A QUALITY PRODUCT QA/QC VALIDATION/QUALIFICATION ROUTINE MONITORING PROCESS COMPONENTS EQUIPMENT ENVIRONMENT RAW MATERIALS

  6. Broad overview of facility and control issues • Appropriate facility design • A controlled environment • Equipment qualification • Adequate measures to control cross contamination • Adequate measures to control mix-up of patient materials

  7. Broad overview of facility and control issues • Control of incoming raw materials • Independent Quality Assurance/Quality Control staff • Records and documentation

  8. Facility Design Principles • Influenced by the nature of the source material • Tissue derived vs Cell culture • Single vs multiproduct operations • Critical manufacturing areas designed for aseptic processing

  9. Facility Design Principles contd. • Process Flow: • Designed to control the manufacturing environment (personnel and process) • Adequate and separate areas for various activities (receipt of materials, testing, manufacturing) • Material Mix-up • Material and personnel flows designed to maximize efficiency and minimize product mix-ups

  10. Environmental Control Air Quality • HEPA-filtered air in manufacturing areas; higher level of control for critical manufacturing steps • Use pressure cascade to protect the product • High pressure to low pressure • Pressure sink to protect other manufacturing areas and personnel

  11. Environmental Control • Need to qualify the HVAC system to confirm that the equipment, its control and circulation systems meet expected performance or quality standards (Monitored under static and dynamic conditions) • Pharmaceutical grade reagents and supplies (Water, Process Air, Utility Gasses)

  12. Process control • Validation • Process (demonstrate manufacturing consistency, aseptic processing) • Equipment • Demonstrate concurrent control over other facility systems (e.g. HVAC) • Qualified personnel

  13. Quality System • Vendor audit • Material qualification • Oversight of process • Change control • Personnel training • Investigation of deviations, recalls, product complaints, Medwatch program

  14. A QUALITY PRODUCT QA/QC VALIDATION/QUALIFICATION ROUTINE MONITORING PROCESS COMPONENTS EQUIPMENT ENVIRONMENT RAW MATERIALS

  15. Aseptic Processing • A processing approach in which product manufacture occurs under environmental and processing conditions that assure minimal opportunity for contamination from the environment or personnel.

  16. Aseptic Processing • Since terminal sterilization is not a feasible option for islets, the final product has to be assembled by introducing the aseptically processed final formulation into a sterilized container and sealed with a sterilized closure system in a high-quality environment

  17. Aseptic Processing • Required for all open manipulations and connections involving product • Involves trained and qualified personnel • Must be validated (media challenge)

  18. Aseptic Processing • Typically occurs in class 100 environment under laminar air flow (BSC) with appropriate environmental monitoring e.g. viable and non-viable airborne particulate monitoring • May also occur in “Closed” systems (Requires validation)

  19. Summary • Design compliance into the facility plans. Advisable to seek CBER input prior to construction. • Establish a thorough qualification/validation program • Maintain an effective QA/QC unit to assure maintenance of quality standards and regulatory compliance

  20. Summary contd. • Maintain aggressive approach to compliance with aseptic processing requirements

  21. Resources For questions on facilities and manufacturing operations, including arrangements for pre-approval inspection: Director Division of Manufacturing and Product Quality FDA, CBER 1401 Rockville Pike, 200S, HFM-670 Rockville, MD 20852-1448 Ph.: (301) 827-3031

  22. Acknowledgement • John A. Eltermann, M.S, R.Ph., Director, DMPQ • John Finkbohner, Ph.D., Deputy Director, DMPQ • DMPQ Review Staff

More Related